Back to search
FDAFDA · Food and drugs·Recall number D-0101-2023

Moxifloxacin Ophthalmic Solution, 0.5%, 3 mL, Rx Only, Packaged and Distributed By: Direct Rx, LLC 94 Worldwide Drive, Dawsonville, GA 30534, NDC 72189-0334-05

Published January 18, 2023 · Recall initiated: November 2, 2022

Summary

FDA records drug Class II recall D-0101-2023, published January 18, 2023 and initiated November 2, 2022. Recalling firm: Direct Rx; Status: Terminated; Reported quantity: 11 bottles; Lot: Lot #: 07MA2232, Exp. 4/30/23. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.

Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

cGMP deviation: discontinue of stability support for product.

What to do

Voluntary: Firm initiated · Letter

Get an email when a new FDA recall like this is published

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Manufacturer
Direct Rx
Distributor
FL
Lot
Lot #: 07MA2232, Exp. 4/30/23
Risk classification
Class II
Area (FDA)
drug
Country
United States

Related recalls

Questions about this recall

Was Moxifloxacin Ophthalmic Solution, 0.5%, 3 mL, Rx Only, Packaged and Distributed By: Direct Rx, LLC 94 Worldwide Drive, Dawsonville, GA 30534, NDC 72189-0334-05 recalled?

Yes. FDA published recall D-0101-2023 on January 18, 2023. Reported hazard: cGMP deviation: discontinue of stability support for product.

What should I do if I have this product?

Voluntary: Firm initiated · Letter